

Sanofi Announces Expanded Proactive Care for a Disease Modifying Therapy in Type 1 Diabetes

Approval marks a major step forward in proactive care for adults and children living with, or at risk of progression in Type 1 diabetes

UNITED ARAB EMIRATES, July 15, 2026 /EINPresswire.com/ -- Sanofi today announced that UAE

“

“This milestone represents a meaningful step forward for Type 1 diabetes care in the UAE. It reflects the country’s continued commitment to bringing scientific progress closer to patients and families”

*Lama Saleh, General Manager
Greater Gulf, General
Medicines at Sanofi*

health authorities have approved expanded indications for an immunomodulatory therapy in Type 1 diabetes, marking a significant milestone in the evolution of care for one of the most complex autoimmune conditions affecting children, adolescents, and adults.

This accelerated approval, reinforcing the UAE’s position as a leading healthcare hub in the Middle East, significantly broadens the scope of proactive care for younger populations. The therapy is now officially approved to delay the onset of Stage 3 Type 1 diabetes in children as young as one year of age and introduces a revolutionary capability of delaying the decline in endogenous insulin production in pediatric patients aged 8 to 17 years who

have been recently diagnosed with Stage 3.

Representing one of the most significant advancement in Type 1 Diabetes care since the discovery of insulin, this disease modifying treatment fundamentally shifts the medical approach from reactive symptom management to active disease interception.

While insulin remains essential and life sustaining for people living with Type 1 diabetes, the ability to intervene earlier in the autoimmune process introduces a fundamentally different ambition for care, not only managing the disease, but helping to delay its clinical progression.

“This milestone represents a meaningful step forward for Type 1 diabetes care in the UAE. It reflects the country’s continued commitment to bringing scientific progress closer to patients and families, while supporting a more proactive approach to chronic disease management,” said Lama Saleh, General Manager Greater Gulf, General Medicines at Sanofi. “We are proud to

contribute to this important shift, working alongside the healthcare community to establish a new, proactive standard of care that actively anticipates the disease, protects beta cell function, and fundamentally enhances the quality of life for both patients and families across the UAE."

Supported by a world class medical infrastructure, the UAE is decisively leading the region in proactive disease management. This approval not only accelerates access to pioneering science but ensures that the local healthcare ecosystem is fully equipped to shift Type 1 diabetes care from an era of reaction to one of active interception.

About Sanofi

About Sanofi: Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

Media contact

For media enquiries, interview requests, or additional information, please contact souad.jallad@sanofi.com

Souad Jallad

Sanofi

+971 52 568 8390

[email us here](#)



Sanofi Type 1 Diabetes

This press release can be viewed online at: <https://www.einpresswire.com/article/926808195>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

